EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Effects of Inhaled β 2 ‐ AR Agonists in Athletes According to the WADA 2025 List: New Insights From a Systematic Review and Meta‐Analysis

Luigino Calzetta iD, Elena Pistocchini, Gian Marco Manzetti, Shima Gholamalishahi, Miriana Cammarata, Saverio Muscoli, Josuel Ora, Paola Rogliani

Scandinavian Journal of Medicine & Science in Sports · 2026

DOI: 10.1111/sms.70197 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Scandinavian Journal of Medicine & Science in Sports, 2026. Verfasst von Luigino Calzetta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Respiratory Clinical Pharmacology, Department of Clinical Science and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: Athletic Performance, Doping in Sports, Adrenergic beta-2 Receptor Agonists, Performance-Enhancing Substances. Die Arbeit nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review and meta‐analysis (CRD420251006746) investigated the impact of inhaled β 2 ‐adrenoceptor (AR) agonists (IBA) with exemption according to the World Anti‐Doping Agency (WADA) 2025 list on athletic performance, respiratory, and cardiovascular outcomes. A key subgroup analysis focused on IBA administered within WADA 2025 permitted dose intervals. Findings indicate that IBA significantly improved sprint time by 0.30 s (95% CI 0.52–0.07) overall, and by 0.27 s (95% CI 0.50–0.05) in healthy subjects, with long‐acting β 2 ‐AR agonists yielding a 0.49 s (95% CI 0.81–0.17) improvement. These sprint time enhancements persisted even at WADA‐permitted doses. Blood lactate levels significantly increased by 0.67 mmol/L (95% CI 0.19–1.14) overall and by 0.65 mmol/L (95% CI 0.17–1.14) in healthy subjects, though this effect was not significant at WADA‐permitted doses. IBA significantly improved forced expiratory volume in 1 s by 0.19 L (95% CI 0.14–0.23) and forced expiratory flow between 25% and 75% by 0.40 L/s (95% CI 0.24–0.56), with lung function improvements confirmed at WADA‐permitted doses. Heart rate significantly increased by 1.40 bpm (95% CI 0.32–2.48). IBA did not influence aerobic performance. When administered within WADA 2025 permitted doses, IBA can provide small but relevant gains in anaerobic performance in healthy individuals, while simultaneously offering therapeutic bronchodilation for athletes with asthma or exercise‐induced bronchoconstriction. Dose restrictions are critical to minimize the risk of performance enhancement that exceeds therapeutic intent and to mitigate adverse effects. Further research is pivotal to ensure that anti‐doping policies align with health standards and ethical considerations for all athletes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Athletic PerformanceDoping in SportsAdrenergic beta-2 Receptor AgonistsPerformance-Enhancing SubstancesHumansAdministration, InhalationLactic AcidForced Expiratory VolumeAthletesRunning

Stichwörter der Autor:innen

airway hyperresponsivenessasthmaathletesdopingexercise performanceinhaled bronchodilatorβ2‐adrenoceptor agonists

Substanzen

Adrenergic beta-2 Receptor AgonistsLactic AcidPerformance-Enhancing Substances

Autor:innen und Institutionen

  • Unit of Respiratory Clinical Pharmacology, Department of Clinical Science and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Division of Cardiology, University Hospital Policlinico "Tor Vergata", Rome, Italy.

ORCID-Profile: Luigino Calzetta

Zitieren

APA

Calzetta, L., Pistocchini, E., Manzetti, G. M., Gholamalishahi, S., Cammarata, M., Muscoli, S., Ora, J., & Rogliani, P. (2026). Effects of Inhaled β 2 ‐ AR Agonists in Athletes According to the WADA 2025 List: New Insights From a Systematic Review and Meta‐Analysis. Scandinavian Journal of Medicine & Science in Sports. https://doi.org/10.1111/sms.70197

Vancouver

Calzetta L, Pistocchini E, Manzetti GM, Gholamalishahi S, Cammarata M, Muscoli S, et al. Effects of Inhaled β 2 ‐ AR Agonists in Athletes According to the WADA 2025 List: New Insights From a Systematic Review and Meta‐Analysis. Scandinavian Journal of Medicine & Science in Sports. 2026. doi:10.1111/sms.70197

BibTeX
@article{Calzetta2026,
  author = {Calzetta, Luigino and Pistocchini, Elena and Manzetti, Gian Marco and Gholamalishahi, Shima and Cammarata, Miriana and Muscoli, Saverio and Ora, Josuel and Rogliani, Paola},
  title = {Effects of Inhaled β 2 ‐ AR Agonists in Athletes According to the WADA 2025 List: New Insights From a Systematic Review and Meta‐Analysis},
  journal = {Scandinavian Journal of Medicine & Science in Sports},
  year = {2026},
  doi = {10.1111/sms.70197}
}
Kostenlos starten →